Coronavirus: Commission approves second contract with Moderna to ensure up to additional 300 million doses
The European Commission yesterday approved a second contract with the pharmaceutical company Moderna, which provides for an additional purchase of 300 million doses (150 million in 2021 and an option to purchase an additional 150 million in 2022) on behalf of all EU Member States. The new contract also provides for the possibility to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.
Yesterday's contract with Moderna builds upon the broad portfolio of vaccines to be produced in Europe, including the already signed contracts with BioNTech/Pfizer, AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, Curevac and Moderna. This diversified vaccines portfolio will ensure Europe has access to 2.6 billion doses, once the vaccines have been proven to be safe and effective.
President of the European Commission, Ursula von der Leyen, yesterday said:
“Today, we are securing 300 million additional doses of the COVID-19 vaccine produced by Moderna, which is already used for vaccination in the European Union. This brings us closer to our major objective: ensure that all Europeans have access to safe and effective vaccines as quickly as possible. With a portfolio of up to 2.6 billion doses, we will be able to provide vaccines not just to our citizens, but to our neighbours and partners as well.”
Stella Kyriakides, Commissioner for Health and Food Safety, yesterday said:
“With this new contract with Moderna, we are adding another 300 million doses of an authorised safe and effective vaccine. It marks another step towards our objective of providing swift access to safe and effective vaccinations to citizens in Europe and beyond over the course of this year. The contract is important not only for the short term needs of the EU, but also for our future work to limit the rapid spread of new variants.”
The Moderna vaccine is based on messenger RNA (mRNA). mRNA plays a fundamental role in biology, transferring instructions from DNA to the cells' protein making machinery. In an mRNA vaccine, these instructions produce harmless fragments of the virus, which the human body uses to build an immune response to prevent or fight disease. When a person is given the vaccine, their cells will read the genetic instructions and produce a spike protein, a protein on the outer surface of the virus which it uses to enter the body's cells and cause disease. The person's immune system will then treat this protein as foreign and produce natural defences – antibodies and T cells – against it.
The Commission has taken a decision to support this vaccine based on a sound scientific assessment, the technology used, the companies' experience in vaccine development and their production capacity to supply the whole of the EU, as well as their capacity to potentially develop a vaccine against coronavirus variants.
Latest News from
The European Pillar of Social Rights: turning principles into actions05/03/2021 10:38:00
The Commission yesterday set out its ambition for a strong Social Europe that focuses on jobs and skills for the future and paves the way for a fair, inclusive and resilient socio-economic recovery. T
Council approves €330 billion cohesion legislative package05/03/2021 09:25:00
The EU is making available over €330 billion for regional and local projects in 2021-2027 through the structural funds to help reduce economic disparities and boost the recovery from the pandemic.
Pay Transparency: Commission proposes measures to ensure equal pay for equal work05/03/2021 08:15:00
The European Commission yesterday presented a proposal on pay transparency to ensure that women and men in the EU get equal pay for equal work.
EIB provides €7.5 million to Austrian artificial intelligence software innovator Cortical.io04/03/2021 16:33:00
The European Investment Bank (EIB) is providing €7.5 million to Cortical.io AG, an Austrian software company developing innovative artificial intelligence technology based on a Natural Language Understanding (NLU) approach that can interpret and process human language text.
Council approves greater corporate transparency for big multinationals04/03/2021 15:25:00
The EU is taking measures to enhance corporate transparency of big multinational companies.
Commission presents updated approach to fiscal policy response to coronavirus pandemic04/03/2021 14:33:00
The European Commission yesterday adopted a Communication providing Member States with broad guidance on the conduct of fiscal policy in the period ahead.
Union of Equality: European Commission presents Strategy for the Rights of Persons with Disabilities 2021-203004/03/2021 13:25:00
The European Commission yesterday presented an ambitious Strategy for the Rights of Persons with Disabilities 2021-2030 to ensure their full participation in society, on an equal basis with others in the EU and beyond, in line with the Treaty on the Functioning of the European Union and the Charter of Fundamental Rights of the European Union, which establish equality and non-discrimination as cornerstones of EU policies.
Team Europe partners with Equity Bank to support Kenyan business and agriculture amid COVID-1904/03/2021 11:33:00
The European Union and the European Investment Bank, working together as Team Europe, are providing €120 million (KES 15.8 billion) of new support for Equity Bank to enhance financing to Kenyan companies most impacted by the COVID-19 crisis.
Opening remarks by Commissioner Dalli on the Strategy for the Rights of Persons with Disabilities 2021-203004/03/2021 10:38:00
Opening remarks given yesterday by Commissioner Dalli on the Strategy for the Rights of Persons with Disabilities 2021-2030.